[ad_1]
CHA Bio Group, the dad or mum of CHA Biotech Co., South Korea’s main stem cell therapeutics developer, has agreed to amass management of Kakao Healthcare Corp. in a deal price 80 billion gained ($54.5 million), forming an alliance that pairs one among Asia-Pacific’s largest scientific networks with Korea’s most recognisable consumer-technology model.
[ad_2]
